Article

Greenberger Explains Why Immunotherapy Will Be an Important Class of Therapies for Blood Cancers

Lee Greenberger, of the Leukemia & Lymphoma Society, explains how immunotherapy research has progressed in hematological cancers and the potential for these burgeoning therapies.

Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, explains how immunotherapy research has progressed in hematological cancers and the potential for these burgeoning therapies. The latest in blood cancer research, including studies involving immunotherapy for Hodgkin lymphoma, were announced at the annual meeting of the American Society of Hematology.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Avoiding smoking, eating a high-fiber diet and routine screenings are key to reducing the risk of recurrence in colorectal or anal cancer.
Expert Offers Surveillance, Lifestyle Guidance After CRC, Anal Cancer
Image of Dr. D'sa
Understanding the Evolution of Waldenström Macroglobulinemia Treatment
Image of doctor.
Early Arterial Thrombosis May Signal Future Cancer Risk
Image of Dr. Deville.
What are the Long-Term Side Effects of Proton Therapy in Prostate Cancer?
Image of carly.
Facing Cancer as an AYA and Navigating Fertility Preservation Choices
Image of man.
Understanding Unique Treatment Options Across Bladder Cancer Care
Image of kelly.
Preparing For Survivorship After Lymphoma Treatment in AYA PatientsPreparing For Survivorship After Lymphoma Treatment in AYA Patients
Robotic and minimally invasive kidney cancer surgery may reduce pain, shorten recovery time and preserve kidney function, according to Dr. Armine Smith.
Robotic Kidney Cancer Surgery May Aid Recovery, Spare Kidney Function
Image of Doctor.
Long-Term Prostate Cancer Data Highlights Risk and Survivorship Needs
Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.
Why Relationships are Key When Caring For Patients With MPNs
Related Content
A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment: © stock.adobe.com.
May 22nd 2025

PMB-CT01 Therapy Induces Complete Remission in Follicular Lymphoma

Spencer Feldman
A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB-102 trial.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of blood cell.
May 12th 2025

Understanding the Evolving Strategies in WM Care and Management

Ryan Scott
An expert reflects on the treatment landscape of Waldenström macroglobulinemia, emphasizing diagnostics, collaboration and managing neuropathy effectively.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Blood cell.
May 8th 2025

Navigating Lymphoma and Survivorship in Adolescents and Young Adults

Ryan Scott
Dr. Kara Kelly discusses the unique challenges that adolescent and young adult patients with cancer face following their diagnosis.
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
May 7th 2025

Managing Lung Inflammation After Chemoradiation and Tagrisso

Dr. Suresh S. Ramalingam
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.